Germany Drug Delivery Devices Market Outlook to 2023-Central Venous Catheters, Infusion Systems, Needle Free Injections and Metered Dose Inhaler Devices
August 2017
162
About the Report
About the Report
Germany Drug Delivery Devices Market Outlook to 2023-Central Venous Catheters, Infusion Systems, Needle Free Injections and Metered Dose Inhaler Devices
Summary
GlobalData's new report, "Germany Drug Delivery Devices Market Outlook to 2023", provides key market data on the Germany Drug Delivery Devices market. The report provides value, in millions of US dollars and volume (in units) within market categories-Central Venous Catheters, Needle Free Injections, Infusion Systems and Metered Dose Inhaler Devices.
The report also provides company shares and distribution shares data for each of these market categories, and global corporate-level profiles of the key market participants. Based on the availability of data for the particular market and country, information related to pipeline products, news and deals is available in the report.
Extensive interviews are conducted with key opinion leaders (KOLs), physicians and industry experts to validate the market size, company share and distribution share data and analysis.
Scope
Market size and company share data for Drug Delivery Devices market categories-Central Venous Catheters, Needle Free Injections, Infusion Systems and Metered Dose Inhaler Devices.
Annualized market revenues (USD million) and volume (units) data for each of the market categories. Data is provided from 2009 to 2016 and forecast to 2023.
2016 company shares and distribution shares data for each of the market categories.
Global corporate-level profiles of key companies operating within the Germany Drug Delivery Devices market.
Key players covered include GlaxoSmithKline Plc, AstraZeneca Plc, Hospira Inc, Becton Dickinson and Co, Boehringer Ingelheim GmbH, Baxter International Inc, Medtronic plc and others.
Reasons to buy
Develop business strategies by identifying the key market categories poised for strong growth in the future.
Develop market-entry and market expansion strategies.
Design competition strategies by identifying who-stands-where in the market.
Develop investment strategies by identifying the key market categories expected to register strong growth in the near future.
What are the key distribution channels and what's the most preferred mode of product distribution-Identify, understand and capitalize.
Products
Products
Drug Delivery Devices, Central Venous Catheters, Needle Free Injections, Infusion Systems, Metered Dose Inhaler Devices, Value (USD), Volume (units), Revenues, Historic Revenues, Forecast Revenues, Average Price, Company Share, Distribution Share by Revenue, Company Share by Revenue, Pipeline Products, News, Deals, Key Companies, GlaxoSmithKline Plc, AstraZeneca Plc, Boehringer Ingelheim GmbH, Pfizer Inc, Merck & Co Inc, Sunovion Pharmaceuticals Inc, Teva Pharmaceutical Industries Ltd, INJEX-Equidyne Systems, Bioject Medical Technologies Inc , Antares Pharma Inc, PharmaJet Inc, MK Global Co., The European Pharma Group, Hospira Inc, Becton Dickinson and Co, Baxter International Inc, Fresenius Kabi AG, Medtronic plc, B. Braun Melsungen AG, Terumo Corp, Smiths Medical, Nipro Corp, JMS Co Ltd
Companies
B. Braun Melsungen AG
Teleflex Inc
GlaxoSmithKline Plc
C. R. Bard Inc
Edwards Lifesciences Corp
AstraZeneca Plc
Boehringer Ingelheim GmbH
Pfizer Inc
Baxter International Inc
Merck & Co Inc
Becton Dickinson and Co
Fresenius Kabi AG
Smiths Medical
Medtronic Plc
Nipro Corp
Hospira Inc
Terumo Corp
Table of Contents
Table of Contents
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 6
1.2 List of Figures 8
2 Introduction 9
2.1 What Is This Report About? 9
2.2 Drug Delivery Devices Market Segmentation 9
2.3 Definitions of Markets Covered in the Report 10
3 Drug Delivery Devices Market, Germany 13
3.1 Drug Delivery Devices Market, Germany, Revenue ($m), 2009-2023 13
3.2 Drug Delivery Devices Market, Germany, Revenue Mix ($m), 2016 15
3.3 Drug Delivery Devices Market, Germany, Category Contribution by Revenue ($m), 2016 16
3.4 Drug Delivery Devices Market, Germany, Category Comparison by Revenue ($m), 2009-2023 17
3.5 Drug Delivery Devices Market, Germany, Revenue ($m), 2009-2016 18
3.6 Drug Delivery Devices Market, Germany, Revenue ($m), 2016-2023 20
3.7 Drug Delivery Devices Market, Germany, Volume (Units), 2009-2023 22
3.8 Drug Delivery Devices Market, Germany, Volume (Units), 2009-2016 24
3.9 Drug Delivery Devices Market, Germany, Volume (Units), 2016-2023 26
3.10 Drug Delivery Devices Market, Germany, Company Share by Revenue ($m), 2016 28
4 Central Venous Catheters Market, Germany 30
4.1 Central Venous Catheters Market, Germany, Revenue Mix ($m), 2016 30
4.2 Central Venous Catheters Market, Germany, Segment Contribution (%), 2016 31
4.1 Central Venous Catheters Market, Germany, Revenue ($m), 2009-2016 32
4.2 Central Venous Catheters Market, Germany, Revenue ($m), 2016-2023 34
4.3 Central Venous Catheters Market, Germany, Volume (Units), 2009-2016 36
4.4 Central Venous Catheters Market, Germany, Volume (Units), 2016-2023 38
4.6 Central Venous Catheters Market, Germany, Distribution Share by Revenue ($m), 2015-2016 40
4.7 Central Venous Catheters Market, Germany, Company Share by Revenue ($m), 2016 41
5 Infusion Systems Market, Germany 43
5.1 Infusion Systems Market, Germany, Revenue Mix ($m), 2016 43
5.2 Infusion Systems Market, Germany, Segment Contribution (%), 2016 44
5.3 Infusion Systems Market, Germany, Revenue ($m), 2009-2016 46
5.4 Infusion Systems Market, Germany, Revenue ($m), 2016-2023 48
5.4.1 Ambulatory Infusion Pumps Market, Germany, Revenue ($m), by Segment, 2009-2016 50
5.4.2 Syringe Pumps Market, Germany, Revenue ($m), by Segment, 2009-2016 52
5.4.3 Ambulatory Infusion Pumps Market, Germany, Revenue ($m), by Segment, 2016-2023 54
5.4.4 Syringe Pumps Market, Germany, Revenue ($m), by Segment, 2016-2023 56
5.5 Infusion Systems Market, Germany, Volume (Units), 2009-2016 58
5.6 Infusion Systems Market, Germany, Volume (Units), 2016-2023 60
5.6.1 Ambulatory Infusion Pumps Market, Germany, Volume (Units), by Segment, 2009-2016 62
5.6.2 Syringe Pumps Market, Germany, Volume (Units), by Segment, 2009-2016 64
5.6.3 Ambulatory Infusion Pumps Market, Germany, Volume (Units), by Segment, 2016-2023 66
5.6.4 Syringe Pumps Market, Germany, Volume (Units), by Segment, 2016-2023 68
5.7 Infusion Systems Market, Germany, Distribution Share by Revenue ($m), 2015-2016 70
5.8 Infusion Systems Market, Germany, Company Share by Revenue ($m), 2016 71
6 Metered Dose Inhaler Devices Market, Germany 73
6.1 Metered Dose Inhaler Devices Market, Germany, Revenue ($m), 2009-2016 73
6.2 Metered Dose Inhaler Devices Market, Germany, Revenue ($m), 2016-2023 74
6.3 Metered Dose Inhaler Devices Market, Germany, Volume (Units), 2009-2016 75
6.4 Metered Dose Inhaler Devices Market, Germany, Volume (Units), 2016-2023 76
6.5 Metered Dose Inhaler Devices Market, Germany, Distribution Share by Revenue ($m), 2015-2016 77
6.6 Metered Dose Inhaler Devices Market, Germany, Company Share by Revenue ($m), 2016 78
7 Needle Free Injections Market, Germany 80
7.1 Needle Free Injections Market, Germany, Revenue ($m), 2009-2016 80
7.2 Needle Free Injections Market, Germany, Revenue ($m), 2016-2023 81
7.3 Needle Free Injections Market, Germany, Volume (Units), 2009-2016 82
7.4 Needle Free Injections Market, Germany, Volume (Units), 2016-2023 83
7.5 Needle Free Injections Market, Germany, Distribution Share by Revenue ($m), 2015-2016 84
7.6 Needle Free Injections Market, Germany, Company Share by Revenue ($m), 2016 85
8 Overview of Key Companies in Germany, Drug Delivery Devices Market 87
8.1 B. Braun Melsungen AG 87
8.1.1 Company Overview 87
8.2 Teleflex Inc 87
8.2.1 Company Overview 87
8.3 GlaxoSmithKline Plc 87
8.3.1 Company Overview 87
8.4 C. R. Bard Inc 87
8.4.1 Company Overview 87
8.5 Edwards Lifesciences Corp 88
8.5.1 Company Overview 88
8.6 AstraZeneca Plc 88
8.6.1 Company Overview 88
8.7 Boehringer Ingelheim GmbH 88
8.7.1 Company Overview 88
8.8 Pfizer Inc 88
8.8.1 Company Overview 88
8.9 Baxter International Inc 89
8.9.1 Company Overview 89
8.10 Merck & Co Inc 89
8.10.1 Company Overview 89
8.11 Becton Dickinson and Co 89
8.11.1 Company Overview 89
8.12 Fresenius Kabi AG 90
8.12.1 Company Overview 90
8.13 Smiths Medical 90
8.13.1 Company Overview 90
8.14 Medtronic Plc 90
8.14.1 Company Overview 90
8.15 Nipro Corp 91
8.15.1 Company Overview 91
8.16 Hospira Inc 91
8.16.1 Company Overview 91
8.17 Terumo Corp 91
8.17.1 Company Overview 91
9 Drug Delivery Devices Market Pipeline Products 92
10 Financial Deals Landscape 98
10.1 Acquisition 98
10.1.1 Dietmar Hopp May Sell its Stake in LTS Lohmann Therapie-Systeme 98
10.1.2 Luye Pharma Acquires Acino and Acino Supply for USD269 Million 99
10.2 Asset Transactions 101
10.2.1 ICU Medical Acquires Hospira Infusion Systems Business from Pfizer 101
10.3 Debt Offerings 103
10.3.1 Fresenius Raises USD742.5 Million in Private Placement of 0.875% Notes Due 2022 103
10.3.2 Fresenius Raises USD742.5 Million in Private Placement of 1.5% Notes Due 2024 104
10.3.3 Fresenius Raises USD742.5 Million in Private Placement of 2.125% Notes Due 2027 105
10.3.4 Fresenius Raises USD530.4 Million in Private Placement of 3% Notes Due 2032 106
10.4 Equity Offerings 107
10.4.1 Magforce Raises USD5.6 Million in Private Placement of Shares 107
10.5 Partnerships 108
10.5.1 Alimera Sciences Enters into Licensing Agreement with pSivida 108
10.5.2 Vetter Pharma International and Microdermics Enter into Agreement 109
10.5.3 Ferring International and Alrise Biosystems Enter into Co-Development Agreement 110
10.5.4 Bluegrass Vascular Enters into Partnership with Merit Medical 111
10.5.5 Aequus Pharma to Enter into Licensing Agreement with Transdermal Research Pharm Labs 112
10.5.6 Valeant Pharma Enters into Licensing Agreement with EyeGate Pharma 113
10.5.7 Propeller Health Enters into Agreement with Novartis Pharma 115
10.5.8 Neuronex Enters Into Licensing Agreement With SK Biopharmaceuticals For DZNS Technology 116
10.5.9 Pfizer Terminates its Licensing Agreement with pSivida 117
10.5.10 BioMed X Enters into Agreement with Merck 118
10.5.11 Bayer Enters into Licensing Agreement with DelSiTech 119
10.5.12 BioCorRx Enters into Licensing Agreement with Therakine 120
10.6 Venture Financing 121
10.6.1 AMW Raises USD6.4 Million in Venture Financing 121
11 Recent Developments 122
11.1 Corporate Communications 122
11.1.1 Jun 29, 2017: Bernhard Kernen named CFO of Raumedic 122
11.1.2 Jun 27, 2017: NOVALIQ Strengthens Executive Management Team with the Appointment of Gabriela Burian, MD, MPH, as Chief Medical Officer 122
11.1.3 May 12, 2017: Constantin Birnstiel to Become Head of Group Communications at Merck 123
11.1.4 Apr 12, 2017: Change in the B. Braun Management Board and the Aesculap Management Board 123
11.1.5 Apr 05, 2017: New member of the Executive Board appointed 123
11.1.6 Mar 28, 2017: Vetter�s Dr. Claudia Roth is appointed to the Fraunhofer Advisory Board 123
11.1.7 Feb 22, 2017: Change in the B. Braun Management Board 124
11.1.8 Feb 07, 2017: Haselmeier Appoints Paul Jansen as Senior Advisor and Member of the Board of Directors 124
11.1.9 Jan 13, 2017: Fresenius Medical Care Announces Leadership Change in North America 124
11.1.10 Jan 09, 2017: leon Appoints Pharma Expert Michael Mehler as Chief Executive Officer 125
11.1.11 Jan 09, 2017: leon-nanodrugs Appoints Pharma Expert Michael Mehler as Chief Executive Officer 125
11.1.12 Oct 31, 2016: TCT 2016: Orsiro Drug-Eluting Stent Proves Non-Inferiority to Resolute Integrity and Synergy Stents 126
11.1.13 Sep 23, 2016: Merck Appoints Isabel De Paoli as Chief Strategy Officer 127
11.1.14 Aug 10, 2016: MagForce announces positive results of 2016 Annual General Meeting 127
11.1.15 Jul 22, 2016: LTS Lohmann Therapie-Systeme Appoints New Chief TechOps Officer 128
11.2 Financial Announcements 128
11.2.1 Jun 30, 2017: MagForce Publishes Financial Results for the Year 2016 and Operative Highlights 128
11.2.2 May 18, 2017: Merck Continues to Grow Profitably in the First Quarter 130
11.2.3 Apr 05, 2017: Successful financial year 2016 for Boehringer Ingelheim 132
11.2.4 Mar 31, 2017: B. Braun continues its sales and earnings growth 133
11.2.5 Oct 27, 2016: Fresenius: Continued strong sales and earnings growth; Lower end of Group earnings guidance raised 134
11.2.6 Sep 30, 2016: MagForce Publishes Financial Results for the First Half of 2016 and Operative Highlights 137
11.2.7 Aug 04, 2016: Merck Lifts Forecast Following Good Second Quarter 139
11.2.8 Aug 01, 2016: Fresenius Medical Care posts accelerated earnings growth in the 2nd quarter 141
11.3 Legal And Regulatory 143
11.3.1 Jan 31, 2017: Fresenius Medical Care reaches agreement on outstanding payments 143
11.3.2 Dec 13, 2016: TUV Certification for the Bengaluru Facility 143
11.3.3 Nov 30, 2016: New Vetter data processing center is officially certified 144
11.4 Other Significant Developments 144
11.4.1 Jul 12, 2017: Merck Refines Western European Life Science Production Site Network 144
11.4.2 Jul 12, 2017: Fresenius Medical Care successfully amends and extends its credit agreement, ahead of schedule 145
11.4.3 Jun 08, 2017: B. Braun is participating in the third edition of the High-Tech Founders Fund 145
11.4.4 Apr 28, 2017: MEDITE Cancer Diagnostics Announces Reorganization of Germany Operations 145
11.4.5 Mar 21, 2017: Merck Accelerator Hits New Peak of Applications 146
11.4.6 Mar 10, 2017: Fresenius Kabi builds new warehouse at Blonie production site 146
11.4.7 Mar 09, 2017: Merck Generates Record Sales and Continues to Grow Profitably in 2016 147
11.4.8 Nov 15, 2016: Merck Raises Profit Forecast for 2016 Following Good Third Quarter 148
11.4.9 Oct 11, 2016: Fresenius Kabi Joins Chicago Health Innovation Incubator MATTER as Newest Strategic Partner 150
11.4.10 Aug 17, 2016: Fresenius Kabi investing nearly $250 million to expand plant near Chicago 150
11.4.11 Aug 03, 2016: Boehringer Ingelheim: Growth in all core businesses 150
11.4.12 Jul 19, 2016: MilliporeSigma Starts Construction on $115 Million Multi-faceted Life Science Campus in Burlington, Massachusetts 151
11.5 Product News 152
11.5.1 May 03, 2017: B. Braun Focused on Peripheral Vascular Access & Hazardous Drug Safety at INS 152
11.6 Strategy And Business Planning 153
11.6.1 Jul 06, 2017: Fresenius Kabi expands production site in Portugal 153
11.6.2 Jun 29, 2017: Merck Expands Packaging Capacity at Swiss Biotech Manufacturing Site of Aubonne 153
11.6.3 Jun 20, 2017: Merck Ventures Creates New Immuno-Oncology Company iOnctura 153
11.6.4 Jun 08, 2017: Fresenius Medical Care sees excellent prospects for further growth and launches a new Global Efficiency Program at its Capital Markets Day 2017 154
11.6.5 May 16, 2017: Merck: Optimizing the Further Development of the Darmstadt Site 154
11.6.6 Apr 20, 2017: Merck Provides Upgraded Manufacturing Capabilities to BioInvent with Single-use Mobius Bioreactors 155
11.6.7 Feb 16, 2017: GSK and EMBL have signed an agreement to enhance understanding of disease and drug mechanisms 155
11.6.8 Nov 22, 2016: HELIOS lays foundation stone for new hospital building in Wiesbaden 156
11.6.9 Oct 13, 2016: Merck Sets its Sights on 2018 and Outlines Future Strategic Roadmap 156
12 Appendix 158
12.1 Research Methodology 159
12.1.1 Coverage 159
12.1.2 Secondary Research 159
12.1.3 Primary Research 160
12.1.4 Company Share Analysis 160
12.1.5 Distribution Share Analysis 160
12.1.6 Benchmarking 161
12.2 GlobalData Consulting 161
12.3 Contact Us 162
12.4 Disclaimer 162
List of Figure
1.2 List of Figures
Figure 1: Drug Delivery Devices Market, Germany, Revenue ($m), USD Constant, 2009-2023 13
Figure 2: Drug Delivery Devices Market, Germany, Revenue Mix ($m), 2016 15
Figure 3: Drug Delivery Devices Market, Germany, Category Contribution (%), 2016 16
Figure 4: Drug Delivery Devices Market, Germany, Category Comparison by Revenue ($m), 2009-2023 17
Figure 5: Drug Delivery Devices Market, Germany, Revenue ($m), USD Constant, Historic, 2009-2016 18
Figure 6: Drug Delivery Devices Market, Germany, Revenue ($m), USD Constant, Forecast, 2016-2023 20
Figure 7: Drug Delivery Devices Market, Germany, Volume (Units), 2009-2023 22
Figure 8: Drug Delivery Devices Market, Germany, Volume (Units), Historic, 2009-2016 24
Figure 9: Drug Delivery Devices Market, Germany, Volume (Units), Forecast, 2016-2023 26
Figure 10: Drug Delivery Devices Market, Germany, Company Share (%) 2016 28
Figure 11: Central Venous Catheters Market, Germany, Revenue Mix ($m), 2016 30
Figure 12: Central Venous Catheters Market, Germany, Segment Contribution (%), 2016 31
Figure 13: Central Venous Catheters Market, Germany, Revenue ($m), USD Constant, Historic, 2009-2016 32
Figure 14: Central Venous Catheters Market, Germany, Revenue ($m), USD Constant, Forecast, 2016-2023 34
Figure 15: Central Venous Catheters Market, Germany, Volume (Units), Historic, 2009-2016 36
Figure 16: Central Venous Catheters Market, Germany, Volume (Units), Forecast, 2016-2023 38
Figure 17: Central Venous Catheters Market, Germany, Company Share (%) 2016 41
Figure 18: Infusion Systems Market, Germany, Revenue Mix ($m), 2016 43
Figure 19: Infusion Systems Market, Germany, Segment Contribution (%), 2016 44
Figure 20: Infusion Systems Market, Germany, Revenue ($m), USD Constant, Historic, 2009-2016 46
Figure 21: Infusion Systems Market, Germany, Revenue ($m), USD Constant, Forecast, 2016-2023 48
Figure 22: Ambulatory Infusion Pumps Market, Germany, Revenue ($m), USD Constant, Historic, 2009-2016 50
Figure 23: Syringe Pumps Market, Germany, Revenue ($m), USD Constant, Historic, 2009-2016 52
Figure 24: Ambulatory Infusion Pumps Market, Germany, Revenue ($m), USD Constant, Forecast, 2016-2023 54
Figure 25: Syringe Pumps Market, Germany, Revenue ($m), USD Constant, Forecast, 2016-2023 56
Figure 26: Infusion Systems Market, Germany, Volume (Units), Historic, 2009-2016 58
Figure 27: Infusion Systems Market, Germany, Volume (Units), Forecast, 2016-2023 60
Figure 28: Ambulatory Infusion Pumps Market, Germany, Volume (Units), Historic, 2009-2016 62
Figure 29: Syringe Pumps Market, Germany, Volume (Units), Historic, 2009-2016 64
Figure 30: Ambulatory Infusion Pumps Market, Germany, Volume (Units), Forecast, 2016-2023 66
Figure 31: Syringe Pumps Market, Germany, Volume (Units), Forecast, 2016-2023 68
Figure 32: Infusion Systems Market, Germany, Company Share (%) 2016 71
Figure 33: Metered Dose Inhaler Devices Market, Germany, Revenue ($m), USD Constant, Historic, 2009-2016 73
Figure 34: Metered Dose Inhaler Devices Market, Germany, Revenue ($m), USD Constant, Forecast, 2016-2023 74
Figure 35: Metered Dose Inhaler Devices Market, Germany, Volume (Units), Historic, 2009-2016 75
Figure 36: Metered Dose Inhaler Devices Market, Germany, Volume (Units), Forecast, 2016-2023 76
Figure 37: Metered Dose Inhaler Devices Market, Germany, Company Share (%) 2016 78
Figure 38: Needle Free Injections Market, Germany, Revenue ($m), USD Constant, Historic, 2009-2016 80
Figure 39: Needle Free Injections Market, Germany, Revenue ($m), USD Constant, Forecast, 2016-2023 81
Figure 40: Needle Free Injections Market, Germany, Volume (Units), Historic, 2009-2016 82
Figure 41: Needle Free Injections Market, Germany, Volume (Units), Forecast, 2016-2023 83
Figure 42: Needle Free Injections Market, Germany, Company Share (%) 2016 85
List of Table
1.1 List of Tables
Table 1: Drug Delivery Devices Market, Germany, Revenue ($m), USD Constant, 2009-2023 14
Table 2: Drug Delivery Devices Market, Germany, Category Contribution by Revenue ($m), 2016 16
Table 3: Drug Delivery Devices Market, Germany, Category Comparison by Revenue ($m), 2009-2023 17
Table 4: Drug Delivery Devices Market, Germany, Revenue ($m), USD Constant, Historic, 2009-2016 19
Table 5: Drug Delivery Devices Market, Germany, Revenue ($m), USD Constant, Forecast, 2016-2023 21
Table 6: Drug Delivery Devices Market, Germany, Volume (Units), 2009-2023 23
Table 7: Drug Delivery Devices Market, Germany, Volume (Units), Historic, 2009-2016 25
Table 8: Drug Delivery Devices Market, Germany, Volume (Units), Forecast, 2016-2023 27
Table 9: Drug Delivery Devices Market, Germany, Company Share by Revenue ($m), USD Constant, 2016 29
Table 10: Central Venous Catheters Market, Germany, Segment Contribution (%), 2016 31
Table 11: Central Venous Catheters Market, Germany, Revenue ($m), USD Constant, Historic, 2009-2016 33
Table 12: Central Venous Catheters Market, Germany, Revenue ($m), USD Constant, Forecast, 2016-2023 35
Table 13: Central Venous Catheters Market, Germany, Volume (Units), Historic, 2009-2016 37
Table 14: Central Venous Catheters Market, Germany, Volume (Units), Forecast, 2016-2023 39
Table 15: Central Venous Catheters Market, Germany, Distribution Share by Revenue ($m), USD Constant, 2015-2016 40
Table 16: Central Venous Catheters Market, Germany, Company Share by Revenue ($m), USD Constant, 2016 42
Table 17: Infusion Systems Market, Germany, Segment Contribution (%), 2016 45
Table 18: Infusion Systems Market, Germany, Revenue ($m), USD Constant, Historic, 2009-2016 47
Table 19: Infusion Systems Market, Germany, Revenue ($m), USD Constant, Forecast, 2016-2023 49
Table 20: Ambulatory Infusion Pumps Market, Germany, Revenue ($m), USD Constant, Historic, 2009-2016 51
Table 21: Syringe Pumps Market, Germany, Revenue ($m), USD Constant, Historic, 2009-2016 53
Table 22: Ambulatory Infusion Pumps Market, Germany, Revenue ($m), USD Constant, Forecast, 2016-2023 55
Table 23: Syringe Pumps Market, Germany, Revenue ($m), USD Constant, Forecast, 2016-2023 57
Table 24: Infusion Systems Market, Germany, Volume (Units), Historic, 2009-2016 59
Table 25: Infusion Systems Market, Germany, Volume (Units), Forecast, 2016-2023 61
Table 26: Ambulatory Infusion Pumps Market, Germany, Volume (Units), Historic, 2009-2016 63
Table 27: Syringe Pumps Market, Germany, Volume (Units), Historic, 2009-2016 65
Table 28: Ambulatory Infusion Pumps Market, Germany, Volume (Units), Forecast, 2016-2023 67
Table 29: Syringe Pumps Market, Germany, Volume (Units), Forecast, 2016-2023 69
Table 30: Infusion Systems Market, Germany, Distribution Share by Revenue ($m), USD Constant, 2015-2016 70
Table 31: Infusion Systems Market, Germany, Company Share by Revenue ($m), USD Constant, 2016 72
Table 32: Metered Dose Inhaler Devices Market, Germany, Revenue ($m), USD Constant, Historic, 2009-2016 73
Table 33: Metered Dose Inhaler Devices Market, Germany, Revenue ($m), USD Constant, Forecast, 2016-2023 74
Table 34: Metered Dose Inhaler Devices Market, Germany, Volume (Units), Historic, 2009-2016 75
Table 35: Metered Dose Inhaler Devices Market, Germany, Volume (Units), Forecast, 2016-2023 76
Table 36: Metered Dose Inhaler Devices Market, Germany, Distribution Share by Revenue ($m), USD Constant, 2015-2016 77
Table 37: Metered Dose Inhaler Devices Market, Germany, Company Share by Revenue ($m), USD Constant, 2016 79
Table 38: Needle Free Injections Market, Germany, Revenue ($m), USD Constant, Historic, 2009-2016 80
Table 39: Needle Free Injections Market, Germany, Revenue ($m), USD Constant, Forecast, 2016-2023 81
Table 40: Needle Free Injections Market, Germany, Volume (Units), Historic, 2009-2016 82
Table 41: Needle Free Injections Market, Germany, Volume (Units), Forecast, 2016-2023 83
Table 42: Needle Free Injections Market, Germany, Distribution Share by Revenue ($m), USD Constant, 2015-2016 84
Table 43: Needle Free Injections Market, Germany, Company Share by Revenue ($m), USD Constant, 2016 86
Table 44: Drug Delivery Devices Market Pipeline Products 92
Table 45: Dietmar Hopp May Sell its Stake in LTS Lohmann Therapie-Systeme 98
Table 46: Luye Pharma Acquires Acino and Acino Supply for USD269 Million 99
Table 47: ICU Medical Acquires Hospira Infusion Systems Business from Pfizer 101
Table 48: Fresenius Raises USD742.5 Million in Private Placement of 0.875% Notes Due 2022 103
Table 49: Fresenius Raises USD742.5 Million in Private Placement of 1.5% Notes Due 2024 104
Table 50: Fresenius Raises USD742.5 Million in Private Placement of 2.125% Notes Due 2027 105
Table 51: Fresenius Raises USD530.4 Million in Private Placement of 3% Notes Due 2032 106
Table 52: Magforce Raises USD5.6 Million in Private Placement of Shares 107
Table 53: Alimera Sciences Enters into Licensing Agreement with pSivida 108
Table 54: Vetter Pharma International and Microdermics Enter into Agreement 109
Table 55: Ferring International and Alrise Biosystems Enter into Co-Development Agreement 110
Table 56: Bluegrass Vascular Enters into Partnership with Merit Medical 111
Table 57: Aequus Pharma to Enter into Licensing Agreement with Transdermal Research Pharm Labs 112
Table 58: Valeant Pharma Enters into Licensing Agreement with EyeGate Pharma 113
Table 59: Propeller Health Enters into Agreement with Novartis Pharma 115
Table 60: Neuronex Enters Into Licensing Agreement With SK Biopharmaceuticals For DZNS Technology 116
Table 61: Pfizer Terminates its Licensing Agreement with pSivida 117
Table 62: BioMed X Enters into Agreement with Merck 118
Table 63: Bayer Enters into Licensing Agreement with DelSiTech 119
Table 64: BioCorRx Enters into Licensing Agreement with Therakine 120
Table 65: AMW Raises USD6.4 Million in Venture Financing 121
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.